

Matthew B Rettig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5934002/publications.pdf>

Version: 2024-02-01

99
papers

6,586
citations

70961

41
h-index

66788

78
g-index

103
all docs

103
docs citations

103
times ranked

9347
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
2	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	0.8	477
3	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
4	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	5.1	338
5	AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression. <i>Journal of Biological Chemistry</i> , 2004, 279, 2737-2746.	1.6	302
6	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	288
7	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. <i>Nature Medicine</i> , 2010, 16, 1414-1420.	15.2	280
8	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
9	High-purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing. <i>Advanced Materials</i> , 2013, 25, 2897-2902.	11.1	142
10	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	0.9	140
11	Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor- κ B-dependent mechanism. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2662-2671.	1.9	129
12	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	5.1	120
13	Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF- κ B and JNK/AP1 pathways. <i>Oncogene</i> , 2003, 22, 3371-3385.	2.6	118
14	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 434-441.	2.8	113
15	Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9986-9991.	3.3	105
16	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	0.9	104
17	Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor κ B Activity. <i>Molecular and Cellular Biology</i> , 2005, 25, 7546-7556.	1.1	100
18	The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. <i>Blood</i> , 2002, 99, 649-654.	0.6	99

#	ARTICLE	IF	CITATIONS
19	Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF- κ B Activation. <i>Cancer Cell</i> , 2008, 14, 394-407.	7.7	98
20	A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. <i>Oncotarget</i> , 2015, 6, 44781-44793.	0.8	94
21	Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. <i>Cell Reports</i> , 2016, 17, 2596-2606.	2.9	94
22	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160.	2.8	94
23	NF- κ B-Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by <i>Von Hippel-Lindau</i> Inactivation in Renal Cell Carcinomas. <i>Cancer Research</i> , 2010, 70, 752-761.	0.4	89
24	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87
25	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 2580-2592.	0.4	85
26	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	2.8	81
27	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	2.8	74
28	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1356-1363.	3.2	71
29	Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. <i>Blood</i> , 2002, 100, 1919-1921.	0.6	69
30	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 304-316.	5.1	68
31	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	2.0	66
32	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	63
33	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 96.	1.1	58
34	VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF- κ B-dependent mechanism. <i>Oncogene</i> , 2005, 24, 1563-1570.	2.6	55
35	Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. <i>Blood</i> , 2004, 103, 222-228.	0.6	52
36	Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 61-69.	1.9	51

#	ARTICLE	IF	CITATIONS
37	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. <i>Molecular Cancer Research</i> , 2019, 17, 1235-1240.	1.5	51
38	Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 1374-1385.	0.4	48
39	<i>p120-Catenin</i> Is Transcriptionally Downregulated by FOXC2 in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , 2010, 8, 762-774.	1.5	46
40	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
41	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	0.9	42
42	Quantitative Magnetic Separation of Particles and Cells Using Gradient Magnetic Ratcheting. <i>Small</i> , 2016, 12, 1891-1899.	5.2	41
43	Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain. <i>Medicinal Research Reviews</i> , 2019, 39, 910-960.	5.0	41
44	Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 727-36.	1.9	41
45	Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4537-45.	3.2	40
46	Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. <i>Urology</i> , 2004, 64, 335-340.	0.5	39
47	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	0.9	37
48	Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone. <i>PLoS ONE</i> , 2016, 11, e0163232.	1.1	35
49	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	3.3	30
50	CD38 is methylated in prostate cancer and regulates extracellular NAD ⁺ . <i>Cancer & Metabolism</i> , 2018, 6, 13.	2.4	28
51	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263072.	2.8	28
52	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	3.4	27
53	aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in ¹⁸ F-DCFPyL Images of Veterans with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 233-239.	2.8	25
54	The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in cancer patients. <i>Precision Clinical Medicine</i> , 2019, 2, 131-139.	1.3	24

#	ARTICLE	IF	CITATIONS
55	YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence. <i>Oncotarget</i> , 2015, 6, 7470-7480.	0.8	23
56	Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1041-1051.	3.3	22
57	Detection Threshold and Reproducibility of ^{68}Ga -PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397.	2.8	21
58	Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor. <i>Scientific Reports</i> , 2020, 10, 1403.	1.6	20
59	Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer. <i>Journal of Biological Chemistry</i> , 2020, 295, 17169-17186.	1.6	19
60	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.3	19
61	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
62	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
63	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€‘Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
64	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e89-e106.	1.8	17
65	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
66	c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 391-404.	1.7	13
67	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€‘Supported West Coast Prostate Cancer Dream Team. <i>European Urology Focus</i> , 2016, 2, 469-471.	1.6	12
68	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 930-935.	0.4	12
69	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
70	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
71	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 135-139.	2.0	11
72	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4616-4624.	3.2	10

#	ARTICLE	IF	CITATIONS
73	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.	3.2	10
74	Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF- κ B and JNK dependent manner. <i>Asian Journal of Urology</i> , 2015, 2, 38-45.	0.5	9
75	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. <i>Radiotherapy and Oncology</i> , 2022, 166, 1-7.	0.3	9
76	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	8
77	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 207-209.	2.0	8
78	Synthesis of β -Amino Diaryldienones Using the Mannich Reaction. <i>Organic Letters</i> , 2019, 21, 4039-4043.	2.4	7
79	The Crossroads of Geriatric Cardiology and Cardio-Oncology. <i>Current Geriatrics Reports</i> , 2015, 4, 327-337.	1.1	6
80	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	2.0	6
81	An 89-Year-Old Man with COVID-19-Associated Coagulopathy Presenting with a Prolonged Partial Thromboplastin Time, Lupus Anticoagulant, and a High Titer of Factor VIII Inhibitor. <i>American Journal of Case Reports</i> , 2020, 21, e926728.	0.3	6
82	Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 739-746.	0.6	5
83	Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on ^{68}Ga -PSMA-11 PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e353-e356.	0.7	5
84	The Impact of ^{18}F -DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 1364-1369.	0.6	5
85	CRK SH3N Domain Diminishes Cell Invasiveness of Non-Small Cell Lung Cancer. <i>Genes and Cancer</i> , 2013, 4, 315-324.	0.6	4
86	Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 549-557.	0.6	4
87	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e9-931.e16.	0.8	4
88	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	2.6	3
89	Leptomeningeal Carcinomatosis of Prostate Cancer: A Case Report and Review of the Literature. <i>Reviews in Urology</i> , 2020, 22, 80-84.	0.9	3
90	Interleukin-6: An antagonizing problem becomes a solution. <i>Nature Biotechnology</i> , 1997, 15, 952-953.	9.4	2

#	ARTICLE	IF	CITATIONS
91	Tumor Cell Isolation: High Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing (Adv. Mater. 21/2013). Advanced Materials, 2013, 25, 2870-2870.	11.1	1
92	Cover Image, Volume 39, Issue 1. Medicinal Research Reviews, 2019, 39, i-i.	5.0	1
93	Response from Rettig, Said and Berenson. Trends in Microbiology, 1997, 5, 425-426.	3.5	0
94	Cover Picture: Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers (Angew. Chem. Int. Ed. 13/2011). Angewandte Chemie - International Edition, 2011, 50, 2857-2857.	7.2	0
95	Rabdosia rubescens inhibition of emergence of androgen-independent prostate cancer. FASEB Journal, 2008, 22, 889.7.	0.2	0
96	Highlights in prostate cancer from the 2021 European Society for Medical Oncology Congress and the 2021 American Urological Association Meeting: commentary.. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 23, 19-23.	0.3	0
97	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. Clinical Advances in Hematology and Oncology, 2022, 20 Suppl 9, 1-20.	0.3	0
98	How patient characteristics can guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. Clinical Advances in Hematology and Oncology, 2022, 20 Suppl 9, 9-12.	0.3	0
99	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.. Clinical Advances in Hematology and Oncology, 2022, 20 Suppl 9, 16-17.	0.3	0